Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

Jacoline E. C. Bromberg*, Samar Issa, Katerina Bakunina, Monique C. Minnema, Tatjana Seute, Marc Durian, Gavin Cull, Harry C. Schouten, Wendy B. C. Stevens, Josee M. Zijlstra, Joke W. Baars, Marcel Nijland, Kylie D. Mason, Aart Beeker, Martini van den Bent, Max Beijert, Michael Gonzales, Daphne de Jong, Jeanette K. Doorduijn

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)216-228
Number of pages13
JournalLancet oncology
Volume20
Issue number2
DOIs
Publication statusPublished - Feb 2019

Keywords

  • NERVOUS-SYSTEM LYMPHOMA
  • WHOLE-BRAIN RADIOTHERAPY
  • HIGH-DOSE METHOTREXATE
  • ELDERLY-PATIENTS
  • IMPROVED SURVIVAL
  • CHEMOTHERAPY
  • IMMUNOCHEMOTHERAPY
  • TEMOZOLOMIDE
  • PROCARBAZINE
  • CYTARABINE

Cite this

Bromberg, J. E. C., Issa, S., Bakunina, K., Minnema, M. C., Seute, T., Durian, M., Cull, G., Schouten, H. C., Stevens, W. B. C., Zijlstra, J. M., Baars, J. W., Nijland, M., Mason, K. D., Beeker, A., van den Bent, M., Beijert, M., Gonzales, M., de Jong, D., & Doorduijn, J. K. (2019). Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet oncology, 20(2), 216-228. https://doi.org/10.1016/S1470-2045(18)30747-2